Log in

Relevant bibliographies by topics / Cataplexy / Journal articles

To see the other types of publications on this topic, follow the link: Cataplexy.

Journal articles on the topic 'Cataplexy'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cataplexy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Reddy, Abhishek, and Mary Halsey Maddox. "1231 Slurred Speech- Unusual Presentation of Cataplexy in Childhood Narcolepsy." Sleep 43, Supplement_1 (2020): A470. http://dx.doi.org/10.1093/sleep/zsaa056.1225.

Full text

Abstract:

Abstract Introduction Narcolepsy, a chronic neurological disorder of excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic/hypnopompic hallucinations, frequently presents in late childhood/early adolescence. Cataplexy, the most specific symptom, presents as transient loss of muscle tone causing weakness. Approximately 80% of children with narcolepsy present with cataplexy1. Report of Case Eight year old African American boy presented to sleep clinic with concerns for excessive daytime sleepiness and slurred speech. Teachers initially referred to speech therapy because of slu

APA, Harvard, Vancouver, ISO, and other styles

2

Coelho, Fernando Morgadinho Santos, Márcia Pradella-Hallinan, Gabriela Rodrigues Alves, et al. "A study of T CD4, CD8 and B lymphocytes in narcoleptic patients." Arquivos de Neuro-Psiquiatria 65, no. 2b (2007): 423–27. http://dx.doi.org/10.1590/s0004-282x2007000300011.

Full text

Abstract:

Narcolepsy is characterized by excessive daytime sleep and cataplexy. Little is known about the possible difference in pathophysiology between patients with or without cataplexy. OBJECTIVE: To quantify T CD4, T CD8 and B lymphocytes in subgroups of patients with narcolepsy and the presence or absence of the HLA-DQB1*0602 allele between groups. METHOD: Our study was prospective and controlled (transversal) with 22 narcoleptic patients and 23 health control subjects. Patients underwent an all-night polysomnographic recording (PSG) and a multiple sleep latency Test (MSLT). The histocompatibility

APA, Harvard, Vancouver, ISO, and other styles

3

Reading, Paul. "Cataplexy." Practical Neurology 19, no. 1 (2018): 21–27. http://dx.doi.org/10.1136/practneurol-2018-002001.

Full text

Abstract:

Remarkably and almost invariably, the clinical phenomenon of cataplexy results from the loss of around 40 000 hypocretin-containing neurones in the lateral hypothalamus in the context of narcolepsy type 1. Cataplexy reflects the dysregulation of rapid-eye-movement (REM) sleep, such that REM-sleep atonia intrudes inappropriately into wakefulness as brief episodes of either focal or total paralysis of voluntary muscle. The semiology of cataplexy differs between adults and children. A defining and enigmatic aspect is that certain emotional stimuli usually trigger the episodes. Cataplexy can be th

APA, Harvard, Vancouver, ISO, and other styles

4

Cao, Michelle, and Christian Guilleminault. "Cataplexy." Scholarpedia 3, no. 1 (2008): 3317. http://dx.doi.org/10.4249/scholarpedia.3317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Siegel, J. M., K. S. Tomaszewski, H. Fahringer, G. Cave, T. Kilduff, and W. C. Dement. "Heart rate and blood pressure changes during sleep-waking cycles and cataplexy in narcoleptic dogs." American Journal of Physiology-Heart and Circulatory Physiology 256, no. 1 (1989): H111—H119. http://dx.doi.org/10.1152/ajpheart.1989.256.1.h111.

Full text

Abstract:

Cataplexy is the abrupt loss of muscle tone experienced by narcoleptics. It is usually precipitated by strong emotions or athletic activity. It has been hypothesized that cardiovascular variables have a role in the triggering of cataplexy. In the present study, we have utilized the narcoleptic canine model to directly investigate changes in heart rate and blood pressure in relation to cataplectic episodes. We found that heart rate increased 18% on average in the 20 s preceding cataplexy onset and then fell during cataplexy. Thus, from a cardiovascular standpoint, cataplexy can be subdivided in

APA, Harvard, Vancouver, ISO, and other styles

6

Egel, Robert T., Anthony Lee, Thomas Bump, and Alexander Javois. "Isolated Cataplexy in the Differential Diagnosis of Drop Attacks: A Case of Successful Clinical Diagnosis and Treatment." Case Reports in Neurological Medicine 2012 (2012): 1–4. http://dx.doi.org/10.1155/2012/757586.

Full text

Abstract:

Drop attacks are sudden spontaneous falls that are not accompanied by alteration of consciousness and are followed by immediate recovery. Cataplexy, which is usually associated with narcolepsy, is one of the causes of drop attacks. We report a patient with the rare condition of cataplexy without associated narcolepsy (isolated cataplexy). Isolated cataplexy should be included in the differential diagnosis when a patient presents with recurrent drop attacks and normal diagnostic test results.

APA, Harvard, Vancouver, ISO, and other styles

7

Mahoney, C. E., W. Zhao, A. Coffey, C. Woods, D. Kroeger, and T. Scammell. "0005 Cataplexy Triggered by Social Cues: A Role for Oxytocin in the Amygdala." Sleep 43, Supplement_1 (2020): A2. http://dx.doi.org/10.1093/sleep/zsaa056.004.

Full text

Abstract:

Abstract Introduction People with narcolepsy type 1 report that cataplexy is triggered most often by positive social experiences such as laughing with friends, yet the mechanisms through which social interaction promotes cataplexy are unknown. We hypothesize a subpopulation of central amygdala neurons that are sensitive to the prosocial neuropeptide, oxytocin (CeAOTR), respond to positive valence and trigger cataplexy. Methods We have used in vivo calcium imaging, chemogenetic and optogenetic approaches to characterize the activity pattern of these neurons and to manipulate their activity stat

APA, Harvard, Vancouver, ISO, and other styles

8

Dauvilliers, Y., N. Foldvary-Schaefer, R. K. Bogan, et al. "0753 Cataplexy-Free Days in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults With Narcolepsy With Cataplexy." Sleep 43, Supplement_1 (2020): A286. http://dx.doi.org/10.1093/sleep/zsaa056.749.

Full text

Abstract:

Abstract Introduction Sodium oxybate (SXB) is a standard of care for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy. JZP-258 is an oxybate product candidate with 92% less sodium. This analysis evaluated cataplexy-free days/week, as a measure of treatment impact, in a placebo-controlled randomized withdrawal study of JZP-258 treatment in patients with narcolepsy. Methods Treatment for cataplexy at study entry included 1) SXB (SXB-only); 2) SXB plus other anticataplectics (SXB+other); 3) anticataplectics other than SXB (other anticataplectics); or 4) cataplexy treatmen

APA, Harvard, Vancouver, ISO, and other styles

9

Coelho, Fernando Morgadinho Santos, Márcia Pradella-Hallinan, Mario Predazzoli Neto, Lia Rita Azeredo Bittencourt, and Sérgio Tufik. "Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in São Paulo." Revista Brasileira de Psiquiatria 31, no. 1 (2009): 10–14. http://dx.doi.org/10.1590/s1516-44462009000100004.

Full text

Abstract:

OBJECTIVE: Narcolepsy (with and without cataplexy) and idiopathic hypersomnia, are disorders with common features but with different HLA-DQB1*0602 allele prevalence. The present study describes the prevalence of HLA-DQB1*0602 allele in narcoleptics with and without cataplexy and in patients with idiopathic hypersomnia. METHOD: Subjects comprised 68 patients who were diagnosed for narcolepsy or idiopathic hypersomnia and 23 healthy controls according to the International Classification of Sleep Disorders-2. Subjects comprised 43 patients with narcolepsy and cataplexy, 11 patients with narcoleps

APA, Harvard, Vancouver, ISO, and other styles

10

Lebedeva, A. V., N. V. Pantina, A. P. Efimenko, et al. "Differential diagnosis of cataplexy and generalized epilepsy. Case report." Medical alphabet, no. 12 (August 12, 2024): 20–23. http://dx.doi.org/10.33667/2078-5631-2024-12-20-23.

Full text

Abstract:

Cataplexy is rare disease, the main clinical features of which are loss of muscle tone without loss of consciousness, associated with specific factors such as laughter, and less often fear, anger or crying. The differential diagnosis of epileptic seizures and cataplexy is often difficult because of similar clinical features. Establishing the diagnosis of cataplexy is important because in most cases it is associated with narcolepsy; in addition, misinterpretation of cataplexy can lead to hyperdiagnosis of epilepsy or wrong efficiency mark of antiepileptic drugs. Clinical and instrumental examin

APA, Harvard, Vancouver, ISO, and other styles

11

Thorpy, Michael, Clete Kushida, Akinyemi Ajayi, Jordan Dubow, and Jennifer Gudeman. "0575 Cataplexy Response With FT218 (Once-Nightly Sodium Oxybate): Post Hoc Responder Analysis From the Phase 3 Rest-ON Clinical Trial." SLEEP 46, Supplement_1 (2023): A252—A253. http://dx.doi.org/10.1093/sleep/zsad077.0575.

Full text

Abstract:

Abstract Introduction In the phase 3 REST-ON trial (NCT02720744), participants with narcolepsy type 1 (NT1) treated with once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release formulation, had significant reductions in cataplexy episodes (ON-SXB vs placebo: 4.5 g, P&lt; 0.05 [post hoc]; 6 , 7.5, and 9 g, all P&lt; 0.001). This post hoc responder analysis further characterized improvements in mean weekly cataplexy episodes in trial participants. Methods In REST-ON, participants aged ≥16 years with NT1/NT2 were randomized 1:1 to double-blind ON-SXB or placebo f

APA, Harvard, Vancouver, ISO, and other styles

12

Hamieh, Mohamad, Jimmy Fraigne, and John Peever. "006 The effect of sodium oxybate on cataplexy in orexin knockout mice." Sleep 44, Supplement_2 (2021): A2—A3. http://dx.doi.org/10.1093/sleep/zsab072.005.

Full text

Abstract:

Abstract Introduction Narcolepsy is a neurological disorder that is characterized by the loss of orexin neurons in the lateral hypothalamus. Cataplexy is a symptom of narcolepsy and is identified by a sudden loss of muscle tone during wakefulness. Cataplexy abruptly interrupts day-to-day activities, and makes activities like driving dangerous and potentially fatal. It is hypothesized that cataplexy occurs due to the intrusion of REM sleep muscle atonia during wakefulness. It has been demonstrated that a GABAergic mechanism is responsible for silencing the REM sleep atonia circuit and preventin

APA, Harvard, Vancouver, ISO, and other styles

13

Matlub, Gulraiz, and Glen Greenough. "0809 Late Onset Narcolepsy With Cataplexy." Sleep 45, Supplement_1 (2022): A350—A351. http://dx.doi.org/10.1093/sleep/zsac079.805.

Full text

Abstract:

Abstract Introduction NT1 is characterized by EDS, cataplexy, sleep related paralysis, and hallucinations. Cataplexy is defined as weakness precipitated by emotions, more commonly with positive emotions and is associated with narcolepsy. Report of Cases: 70 yo with history of OSA on APAP referred with year history of worsening EDS, dream enactment, and cataplexy. Initially CPAP titration followed by MSLT was performed. Unfortunately sleep logs/actigraphy were not performed. CPAP was titrated 7-10 cm demonstrating suboptimal control (AHI 30) and presence of RSWA. MSLT demonstrated MSL of 2.9 mi

APA, Harvard, Vancouver, ISO, and other styles

14

Nikolic-Djurovic, Marina, Alberto Pereira, Zvezdana Jemuovic, et al. "Cataplexy in a patient treated for prolactinoma: Case report." Vojnosanitetski pregled 74, no. 8 (2017): 782–85. http://dx.doi.org/10.2298/vsp160118102n.

Full text

Abstract:

Introduction. Isolated cataplexy, without the presence of narcolepsy, is a relatively rare condition, and can be regarded as attacks of motor inhibition with loss of muscle tone and areflexia. The diagnosis of cataplexy relies on the clinical presentation and medical history and it is rarely confirmed by video-polygraph. We here described a female patient treated for prolactinoma who developed isolated cataplexy. Case report. A 53-year-old female treated with bromocriptine for a macroprolactinoma presented with sudden episodes of weakness and toneless legs leading to falls and injuries on seve

APA, Harvard, Vancouver, ISO, and other styles

15

Tachibana, Naoko, Takenao Mihara, Naoko Sugita, Naohiro Egawa, and Toshiaki Hamano. "0604 Diagnostic Delay and Its Causes in Narcolepsy Type 1 in Japan : with special emphasis on cataplexy." SLEEP 46, Supplement_1 (2023): A265. http://dx.doi.org/10.1093/sleep/zsad077.0604.

Full text

Abstract:

Abstract Introduction Although narcolepsy type 1 is characterized by the pathognomonic symptom of cataplexy, it has been reported that there is long diagnostic delay in various countries. However, the causes of this delay have not been studied enough except for European counties. Japan is in a unique position in that all the people have public medical insurance coverage that allows them to have unlimited direct access to any medical specialists, therefore, once the patients experienced cataplexy, theoretically they could consult their symptom to sleep specialists with no financial burden. Unde

APA, Harvard, Vancouver, ISO, and other styles

16

Irukayama-Tomobe, Yoko, Yasuhiro Ogawa, Hiromu Tominaga, et al. "Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models." Proceedings of the National Academy of Sciences 114, no. 22 (2017): 5731–36. http://dx.doi.org/10.1073/pnas.1700499114.

Full text

Abstract:

Narcolepsy-cataplexy is a debilitating disorder of sleep/wakefulness caused by a loss of orexin-producing neurons in the lateroposterior hypothalamus. Genetic or pharmacologic orexin replacement ameliorates symptoms in mouse models of narcolepsy-cataplexy. We have recently discovered a potent, nonpeptide OX2R-selective agonist, YNT-185. This study validates the pharmacological activity of this compound in OX2R-transfected cells and in OX2R-expressing neurons in brain slice preparations. Intraperitoneal, and intracerebroventricular, administration of YNT-185 suppressed cataplexy-like episodes i

APA, Harvard, Vancouver, ISO, and other styles

17

Sahidu, Ghalvan, and Zamroni Afif. "NARKOLEPSI: PATOFISIOLOGI, DIAGNOSIS DAN MANAJEMEN." Unram Medical Journal 9, no. 1 (2020): 1–12. http://dx.doi.org/10.29303/jku.v9i1.401.

Full text

Abstract:

Narkolepsi telah dikenal lama oleh profesi medis. Narkolepsi sangat mengganggu karena tidur dan bangun menjadi tidak teratur. Cataplexy adalah sebuah gejala yang paling sering dikaitkan dengan narkolepsi, meski ada banyak gejala lainnya yang menyertai penyakit gangguan tidur. Narkolepsi dengan cataplexy (tipe 1) bisa langsung didiagnosis. Diagnosa narkolepsi tanpa cataplexy (tipe 2) sering sulit karena hasil diagnosanya perlu diuji dan batasannya pun perlu dipahami. Narkolepsi sering dianggap pemicu terjadinya komorbiditas multipel.

APA, Harvard, Vancouver, ISO, and other styles

18

Muhammad Ghalvan Sahidu and Zamroni Afif. "NARKOLEPSI: PATOFISIOLOGI, DIAGNOSIS DAN MANAJEMEN." Unram Medical Journal 9, no. 1 (2020): 1–12. http://dx.doi.org/10.29303/jku.v9i1.4271.

Full text

Abstract:

Narkolepsi telah dikenal lama oleh profesi medis. Narkolepsi sangat mengganggu karena tidur dan bangun menjadi tidak teratur. Cataplexy adalah sebuah gejala yang paling sering dikaitkan dengan narkolepsi, meski ada banyak gejala lainnya yang menyertai penyakit gangguan tidur. Narkolepsi dengan cataplexy (tipe 1) bisa langsung didiagnosis. Diagnosa narkolepsi tanpa cataplexy (tipe 2) sering sulit karena hasil diagnosanya perlu diuji dan batasannya pun perlu dipahami. Narkolepsi sering dianggap pemicu terjadinya komorbiditas multipel.

APA, Harvard, Vancouver, ISO, and other styles

19

Toth, Brandon, Christian Burgess, and Katie Chang. "0039 Investigating the role of striatal dopamine in sleep and narcolepsy-cataplexy." SLEEP 46, Supplement_1 (2023): A18. http://dx.doi.org/10.1093/sleep/zsad077.0039.

Full text

Abstract:

Abstract Introduction Dopamine release in the striatum is known to govern reward, motor, and sleep behaviors. There also exists a link between pharmacological manipulation of dopamine receptors and cataplexy occurrence, yet the precise spatial and temporal dynamics of dopamine release in relation to cataplexy onset are not understood. In the present study, we evaluate dopamine release dynamics in orexin knockout (OX KO) mice during cataplexy and physiological behaviors. Methods OX KO mice were implanted with EEG/EMG electrodes, and dLight1.1 was expressed in the nucleus accumbens core (NAcc),

APA, Harvard, Vancouver, ISO, and other styles

20

Millichap, J. Gordon. "Narcolepsy and Cataplexy." Pediatric Neurology Briefs 12, no. 2 (1998): 10. http://dx.doi.org/10.15844/pedneurbriefs-12-2-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

De la Herrán-Arita, Alberto K., Ana C. Equihua-Benítez, and René Drucker-Colín. "Treatment of cataplexy." Expert Opinion on Orphan Drugs 1, no. 3 (2013): 199–210. http://dx.doi.org/10.1517/21678707.2013.765359.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Com, Gulnur, Mali A. Einen, and Supriya Jambhekar. "Narcolepsy With Cataplexy." Clinical Pediatrics 54, no. 1 (2014): 5–14. http://dx.doi.org/10.1177/0009922814526301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Krahn, Lois E., and Heydy L. Gonzalez-Arriaza. "Narcolepsy With Cataplexy." American Journal of Psychiatry 161, no. 12 (2004): 2181–84. http://dx.doi.org/10.1176/appi.ajp.161.12.2181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Desarkar, Pushpal, Nishant Goyal, and Christopher R. J. Khess. "Clozapine-Induced Cataplexy." Journal of Neuropsychiatry and Clinical Neurosciences 19, no. 1 (2007): 87–88. http://dx.doi.org/10.1176/jnp.2007.19.1.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Dauvilliers, Yves, Isabelle Arnulf, and Emmanuel Mignot. "Narcolepsy with cataplexy." Lancet 369, no. 9560 (2007): 499–511. http://dx.doi.org/10.1016/s0140-6736(07)60237-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Houghton, William C., Thomas E. Scammell, and Michael Thorpy. "Pharmacotherapy for cataplexy." Sleep Medicine Reviews 8, no. 5 (2004): 355–66. http://dx.doi.org/10.1016/j.smrv.2004.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Davis, Craig, Donna Zarycranski, Markiyan Doliba, Jeffrey Dayno, and Jean-Charles Schwartz. "505 Efficacy of Pitolisant in the Treatment of Cataplexy in Adults With Narcolepsy." Sleep 44, Supplement_2 (2021): A199. http://dx.doi.org/10.1093/sleep/zsab072.504.

Full text

Abstract:

Abstract Introduction Pitolisant was initially approved by the FDA in 2019 for the treatment of excessive daytime sleepiness in adult patients with narcolepsy; in 2020, the indication was expanded to include the treatment of cataplexy. Methods Cataplexy data from 7- or 8-week, randomized, placebo-controlled studies (HARMONY-CTP, HARMONY-1) are reviewed and summarized. In HARMONY-CTP, all patients were required to have ≥3 cataplexy attacks per week at baseline; HARMONY-1 enrolled patients with narcolepsy with or without cataplexy. Pitolisant was individually titrated to a maximum potential dose

APA, Harvard, Vancouver, ISO, and other styles

28

Lopes, Caroline dos Reis, Cláudia Loureiro Gomes, and Núria Madureira. "Narcolepsy - when diagnosis doesn't meet all the criteria – case report." Brazilian Journal of Health Review 6, no. 5 (2023): 19481–86. http://dx.doi.org/10.34119/bjhrv6n5-002.

Full text

Abstract:

Narcolepsy is a rare chronic sleep disorder characterized by a pentad of clinical symptoms: excessive daytime sleepiness, cataplexy, hypnagogic or hypnopompic hallucinations, sleep paralysis and disturbance of nocturnal sleep. The presence of cataplexy defines Narcolepsy Type 1 (NT1), an auto-immune disease with destruction of hypocretin -1 (hcrt1) neurons and low hcrt1 levels in cerebrospinal fluid (CSF). We present a case of an adolescent with excessive daytime sleepiness and cataplexy with normal levels of hcrt1 in CSF. The literature describes about ten percent of NT1 cases with normal CSF

APA, Harvard, Vancouver, ISO, and other styles

29

Bogan, Richard, Thomas Stern, Bruce Corser, et al. "0578 Clinician and Patient Global Impression in a Phase 2 Study of Mazindol (NLS-1021) in Adults with Narcolepsy Type 1 and Type 2." SLEEP 46, Supplement_1 (2023): A254. http://dx.doi.org/10.1093/sleep/zsad077.0578.

Full text

Abstract:

Abstract Introduction Mazindol is the first partial orexin 2 receptor agonist and triple monoamine reuptake inhibitor in development for the treatment of narcolepsy. Clinician and Patient Global Impression (CGI and PGI, respectively) for cataplexy and excessive daytime sleepiness were assessed as secondary endpoints in the phase 2 (POLARIS, NLS-1021) multicenter study of mazindol ER in adult participants with narcolepsy type 1 (NT1) or type 2 (NT2) (ClinicalTrials.gov Identifier: NCT04923594). Methods Adults diagnosed with NT1 or NT2 who were washed out of narcolepsy medications at baseline we

APA, Harvard, Vancouver, ISO, and other styles

30

Badami, Varun, and Dale Jun. "0984 Near Drowning: A Complex Case of Somnolence and Weakness." SLEEP 46, Supplement_1 (2023): A434. http://dx.doi.org/10.1093/sleep/zsad077.0984.

Full text

Abstract:

Abstract Introduction Narcolepsy is a disorder of sleep characterized by pathologic daytime sleepiness classically divided into two major subtypes – those with or without cataplexy. The underlying pathophysiologic mechanism is thought to be related to hypocretin/orexin; pathologically low levels of hypocretin characterize narcolepsy with cataplexy. We present a complex case of weakness in a patient evaluated for narcolepsy. Report of case(s) A 38 year-old male with a BMI of 33 presented with a decade of daytime sleepiness and sudden debilitating attacks of muscle weakness. He underwent level I

APA, Harvard, Vancouver, ISO, and other styles

31

Van Dijk, J. G., G. J. Lammers, and B. A. Blansjaar. "Isolated Cataplexy of more than 40 Years' Duration." British Journal of Psychiatry 159, no. 5 (1991): 719–21. http://dx.doi.org/10.1192/bjp.159.5.719.

Full text

Abstract:

For over 40 years, a 55-year-old woman had suffered from cataplexy, which had been mistakenly identified as hysteria. Sleepiness, hypnagogic hallucinations and sleep-onset paralysis were not present. This is the longest duration of isolated cataplexy reported so far.

APA, Harvard, Vancouver, ISO, and other styles

32

Joyal, Adam, Akihiro Yamanaka, Thomas Scammell, and Alissa Coffey. "001 Exploring the Orexin-tTA/TetO-DTA Mouse as a Model for Pediatric Narcolepsy." Sleep 44, Supplement_2 (2021): A1. http://dx.doi.org/10.1093/sleep/zsab072.000.

Full text

Abstract:

Abstract Introduction Narcolepsy is a sleep disorder caused by selective death of the orexin neurons that often begins in childhood. Orexin neuron loss disinhibits REM sleep during the active period and produces cataplexy, an abnormal behavioral state between REM sleep and wakefulness. Cataplexy is often more severe when narcolepsy develops in children compared to adults, but the mechanisms underlying this difference remain unknown. Methods We used orexin-tTA/TetO-DTA mice to model narcolepsy at different ages. When doxycycline is removed from the diet, the orexin neurons of these mice express

APA, Harvard, Vancouver, ISO, and other styles

33

Seneviratne, U., and K. Puvanendran. "Narcolepsy in Singapore: Is it an Elusive Disease?" Annals of the Academy of Medicine, Singapore 34, no. 1 (2005): 90–93. http://dx.doi.org/10.47102/annals-acadmedsg.v34n1p90.

Full text

Abstract:

Introduction: The aims of the study were to determine the demographic, clinical, and polysomnographic characteristics of narcolepsy, and to address the difficulties in diagnosing narcolepsy and cataplexy, which is a cardinal symptom. We also ventured to investigate the differences between narcolepsy with and without cataplexy. Materials and Methods: Data were collected retrospectively from patients diagnosed with narcolepsy at the Sleep Disorder Unit of Singapore General Hospital over 5 years. Each patient had had a detailed clinical evaluation and overnight polysomnography (PSG) followed by a

APA, Harvard, Vancouver, ISO, and other styles

34

Buntak, Vesna, Kiran Masroor, and Jacqueline Geer. "1197 Cataplexy - Management Conundrums." SLEEP 47, Supplement_1 (2024): A511. http://dx.doi.org/10.1093/sleep/zsae067.01197.

Full text

Abstract:

Abstract Introduction Creating a guideline for the management of patients with narcolepsy is complex due to the number of potential mechanisms that could account for the increased risk of perioperative complications: aggravation of narcolepsy itself, dysautonomia, narcolepsy-related medications, anesthesia interactions, etc. Report of case(s) An 80-year-old woman with a history of narcolepsy type 1, depression, restless leg syndrome, obstructive sleep apnea, and atrial fibrillation presented to our sleep clinic to establish care. Her narcolepsy was managed with strategic naps, but no medicatio

APA, Harvard, Vancouver, ISO, and other styles

35

Geil, Eric S., Christian Agudelo, Kori Ascher, Xiaoyan Sun, Naymee Velez-Ruiz, and Alberto R. Ramos. "1230 An unusual presentation of dementia with Lewy bodies in a septuagenarian." Sleep 43, Supplement_1 (2020): A469—A470. http://dx.doi.org/10.1093/sleep/zsaa056.1224.

Full text

Abstract:

Abstract Introduction Dementia with Lewy bodies (DLB) can be associated with degeneration of the hypocretin system and reduced hypocretin levels. However, reports of DLB initially presenting with narcolepsy with cataplexy symptoms are sparse. Report of Case A 77-year-old man presents with two years of new onset hypersomnia, tremors, memory difficulties, and gait instability. Before his sleep evaluation, he was started on levetiracetam for suspected seizures and levodopa for suspected Parkinson’s disease, without improvement. During his evaluation for hypersomnia, he reported loud snoring, witn

APA, Harvard, Vancouver, ISO, and other styles

36

Wells, Audrey, David Albers, Markiyan Doliba, Donna Zarycranski, Jean-Charles Schwartz, and Jeffrey Dayno. "0577 Clinically Meaningful Improvements With Pitolisant in Adults With Narcolepsy: Pooled Analysis of Randomized Clinical Trials." SLEEP 46, Supplement_1 (2023): A253—A254. http://dx.doi.org/10.1093/sleep/zsad077.0577.

Full text

Abstract:

Abstract Introduction Narcolepsy is characterized by symptoms indicative of sleep–wake dysregulation, notably excessive daytime sleepiness (EDS) and cataplexy. In 2021, the American Academy of Sleep Medicine (AASM) updated its clinical practice guidelines on the treatment of central disorders of hypersomnolence. The AASM identified clinical significance thresholds (CSTs) of a 2-point reduction in Epworth Sleepiness Scale (ESS) score and a 25% reduction in the frequency of cataplexy, amongst others, to compare posttreatment effects between intervention and placebo. This post hoc analysis evalua

APA, Harvard, Vancouver, ISO, and other styles

37

Flosnik, Dawn L., Bernadette M. Cortese, and Thomas W. Uhde. "Cataplexy in Anxious Patients." Journal of Clinical Psychiatry 70, no. 6 (2009): 810–16. http://dx.doi.org/10.4088/jcp.08m04272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Thorpy, Michael J. "Cataplexy Associated with Narcolepsy." CNS Drugs 20, no. 1 (2006): 43–50. http://dx.doi.org/10.2165/00023210-200620010-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Yokota, T., T. Shimizu, H. Hayashi, K. Hirose, and H. Tanabe. "F-response during cataplexy." Journal of Neurology, Neurosurgery & Psychiatry 55, no. 1 (1992): 75–76. http://dx.doi.org/10.1136/jnnp.55.1.75.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Quinto, Christine, Ingela Danielsson, Charles Gellido, Howard Sander, and Sudhansu Chokroverty. "Brainstem Hyperexcitability During Cataplexy." Journal of Clinical Neurophysiology 22, no. 4 (2005): 275–78. http://dx.doi.org/10.1097/01.wnp.0000167933.33532.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lopez, Régis, and Yves Dauvilliers. "Pharmacotherapy options for cataplexy." Expert Opinion on Pharmacotherapy 14, no. 7 (2013): 895–903. http://dx.doi.org/10.1517/14656566.2013.783021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Nolan, B. "Post-H1N1 Narcolepsy-Cataplexy." Yearbook of Neurology and Neurosurgery 2011 (January 2011): 162–65. http://dx.doi.org/10.1016/j.yneu.2011.04.072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Matos, Nuria, Carles Gaig, Joan Santamaria, and Alex Iranzo. "Cataplexy causing subdural hematomas." Sleep Medicine 30 (February 2017): 15–16. http://dx.doi.org/10.1016/j.sleep.2016.01.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bartolini, Ilaria, Fabio Pizza, Andrea Di Luzio, et al. "Automatic detection of cataplexy." Sleep Medicine 52 (December 2018): 7–13. http://dx.doi.org/10.1016/j.sleep.2018.07.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Hasegawa, E., T. Maejima, T. Yoshida, et al. "Neural circuits of cataplexy." Sleep Medicine 64 (December 2019): S148. http://dx.doi.org/10.1016/j.sleep.2019.11.405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Dauvilliers, Yves, Jacques Montplaisir, Valérie Cochen, et al. "Post-H1N1 Narcolepsy-Cataplexy." Sleep 33, no. 11 (2010): 1428–30. http://dx.doi.org/10.1093/sleep/33.11.1428.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mattarozzi, Katia, Claudia Bellucci, Claudio Campi, et al. "Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy." Sleep Medicine 9, no. 4 (2008): 425–33. http://dx.doi.org/10.1016/j.sleep.2007.05.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Nadhim, A., J. Wong, and D. Gupta. "1270 Wobbly Knees: Cataplexy Or Seizure? A Case Report." Sleep 43, Supplement_1 (2020): A483. http://dx.doi.org/10.1093/sleep/zsaa056.1264.

Full text

Abstract:

Abstract Introduction Cataplexy (associated with narcolepsy) is difficult to differentiate from conditions such as seizure, syncope or TIA, but using validated clinical tools can help. We report a case that was mistakenly diagnosed as cataplexy, delaying diagnosis and treatment of his underlying seizures. Report of Case A 42 years old male presented with “freezing spells” described as spontaneous episodes of weakness in his knees. He may stagger and drop objects but had never fallen. He denies loss of consciousness. Post-ictally, he takes a moment to readjust his body and returns to baseline.

APA, Harvard, Vancouver, ISO, and other styles

49

Kewalramani, Anjali, Courtney Molina, and Alon Avidan. "1142 Atypical Cataplexy and Post LP Headaches in POTS with Features of Narcolepsy Type I." SLEEP 47, Supplement_1 (2024): A490. http://dx.doi.org/10.1093/sleep/zsae067.01142.

Full text

Abstract:

Abstract Introduction Postural Orthostatic Tachycardia Syndrome (POTS) consists of orthostatic intolerance upon standing resulting in lightheadedness or fainting. Narcolepsy type I (Narcolepsy with cataplexy) is a disorder of hypersomnolence categorized by cataplexy and impaired hypocretin levels in the hypothalamus. The diagnostic criteria for type 1 narcolepsy include the presence of cataplexy or cerebrospinal fluid orexin-A/hypocretin-1 ≤ 110 pg/mL. Recent data reveals the increased prevalence of POTS in narcolepsy, particularly NT1 phenotype. We present two patients with POTS and features

APA, Harvard, Vancouver, ISO, and other styles

50

Kantimirova, E. A., and D. V. Dmitrenko. "Issues related to differential diagnosis of epilepsy and narcolepsy." Epilepsy and paroxysmal conditions 16, no. 4 (2025): 327–32. https://doi.org/10.17749/2077-8333/epi.par.con.2024.197.

Full text

Abstract:

A differential diagnosis of epileptic and non-epileptic paroxysms is particularly difficult to conduct during a neurologist consultation. Narcolepsy is a chronic disease that causes excessive daytime sleepiness. Some narcolepsy symptoms, especially cataplexy, can be mistakenly interpreted as epileptic seizures. The clinical case demonstrates an importance for interdisciplinary approach to differential diagnosis of epileptic seizures. Clinical markers of typical and atypical cataplexy manifestations are presented.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!